Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYAD-02 in Relapsed/Refractory AML or MDS
NCT04167696Phase 1Recruiting
- Sponsor
- Celyad Oncology
- Start
- Nov 2019
- Primary completion
- Dec 2021
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 2
01
Overview
Phase 1, open-label trial of CYAD-02 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (3 arms), sponsored by Celyad Oncology. Primary endpoint: Occurrence of Dose Limiting Toxicities. Started Nov 2019; status: recruiting.
02
Drugs
CYAD-02
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04167696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04167696.